Avadel Pharmaceuticals plc EBIT

The latest EBIT for AVDL is $6.1M as of September 2025. That compares with $-64M in the prior-year period — up 109.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Avadel Pharmaceuticals plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, AVDL's EBIT moved from $-64M to $6.1M — a 109.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Avadel Pharmaceuticals plc's operating scale or balance-sheet position.

Against Healthcare companies, AVDL currently prints $6.1M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Avadel Pharmaceuticals plc's growth, margins, and balance sheet.

A EBIT figure of $6.1M for AVDL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting AVDL's EBIT ($6.1M), review year-over-year change from $-64M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.